Interstitial fibrosis is recognised as the best histological predictor of progressive renal disease. Myofibroblasts contribute to this process through several functions including hyperproliferation, collagen and collagenase synthesis and reorganisation of extracellular matrix. Recent limited in vitro studies suggest that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors may reduce renal injury not only through their lipid-lowering effects but also by antagonising myofibroblast function. This study therefore examined the effects of lovastatin on the above interstitial myofibroblast behaviours in vitro. Primary cultures of rat renal cortical myofibroblasts were grown by explantation and characterised by immunohistochemistry. Dose response effects of lovastatin (0, 15, 30 µM) in DMEM and 10% FCS were examined on myofibroblast kinetics, total collagen synthesis, collagen I lattice contraction and actin filament rearrangement. Lovastatin decreased myofibroblast proliferation and growth. Likewise, collagen I lattice contraction and actin filament rearrangement were partially inhibited when lovastatin was added at 30 µM. In addition, lovastatin decreased both collagen and collagenase synthesis. Our results suggest that myofibroblast function may be downregulated by lovastatin in vitro. Although a decrease in myofibroblast activity may offer potential benefit in the prevention of progressive scarring, further studies will be necessary to determine the relative importance of these functions.

Keywords:
Renal, Fibroblast, Collagen, HMG-CoA reductase inhibitor
1.
Gonzalez-Avila G, Vadillo-Otega F, Perez-Tamayo R: Experimental diffuse interstitial renal fibrosis. Lab Invest 1988;59:245–252.
2.
Wardle E: Modulatory proteins and processes in alliance with immune cells, mediators, and extracellular proteins in renal interstitial fibrosis. Renal Failure 1999;21:121–133.
3.
Hewitson T, Becker G: Myofibroblast involvement in renal interstitial fibrosis. Nephrology 1996;2:229–234.
4.
Mitchell J, Woodcock-Mitchell J, Reynolds S, Low R, Leslie K, Adler K, Gabbiani G, Skalli O: Alpha-smooth muscle actin in parenchymal cells of bleomycin-induced rat lung. Lab Invest 1989;60:643–650.
5.
Leslie K, Taatjes D, Schwartz J, von Turkovich M, Low R: Cardiac myofibroblasts express alpha smooth muscle actin during right ventricular pressure overload in the rabbit. Am J Pathol 1991;139:207–216.
6.
Sappino A, Schurch W, Gabbiani G: Differentiation of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest 1990;63:144–161.
7.
Darby I, Skalli O, Gabbiani G: Alpha smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest 1990;63:21–29.
8.
Alvarez R, Sun M, Haverty T, Iozzo R, Myers J, Neilson E: Biosynthetic and proliferative characteristics of tubulointerstitial fibroblasts probed with paracrine cytokines. Kidney Int 1992;41:14–23.
9.
Hewitson T, Wu H, Becker G: Interstitial myofibroblasts in experimental renal infection and scarring. Am J Nephrol 1995;15:411–417.
10.
Lewis M, Fine L, Norman J: Pexicrine effects of basement membrane components on paracrine signaling by renal tubular cells. Kidney Int 1996;49:48–58.
11.
Kelynack K, Hewitson T, Pedagogos E, Nicholls K, Becker G: Renal myofibroblasts contract collagen I matrix lattices in vitro. Am J Nephrol 1999;19:694–701.
12.
Rosenson R, Tangney C: Antiatherothrombotic properties of statins. JAMA 1998;279:1643–1650.
13.
Nishimura M, Tanaka T, Yasuda T, Kurakata S, Kitagawa M, Yamada K, Saito Y, Hirai A: Effect of pravastatin on type IV collagen secretion and mesangial cell proliferation. Kidney Int 1999;56(suppl 71):S97–S100.
14.
Johnson D, Saunders H, Field M, Pollock C: In vitro effects of simvastatin on tubulointerstitial cells in a human model of cyclosporin nephrotoxicity. Am J Physiol 1999;276:F467–F475.
15.
Hewitson T, Darby I, Bisucci T, Jones C, Becker G: Evolution of tubulointerstitial fibrosis in experimental renal infection and scarring. J Am Soc Nephrol 1998;9:632–642.
16.
Vrtovsnik F, Couette S, Prie D, Lallemand D, Friedlander G: Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 1997;52:1016–1027.
17.
Johnson D, Saunders H, Brew B, Ganesan A, Baxter R, Poronnik P, Cook I, Gyory A, Field M, Pollock C: Human renal fibroblasts modulate proximal tubule cell growth and transport via the IGF-I axis. Kidney Int 1997;52:1486–1496.
18.
Fenton R, Kung H, Longo D, Smith M: Regulation of intracellular actin polymerisation by prenylated cellular proteins. J Cell Biol 1992;117:347–356.
19.
Ronnov-Jessen L, Petersen O: A function for filamentous α-smooth muscle actin: retardation of motility in fibroblasts. J Cell Biol 1996;134:67–80.
20.
Hewitson T, Martic M, Kelynack K, Pedagogos E, Becker G: Pentoxifylline reduces in vitro renal myofibroblast proliferation and collagen secretion. Am J Nephrol 2000;20:82–88.
21.
Plumb J, Milroy R, Kaye S: Effects of the pH dependence of 3,(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 1989;49:4435–4440.
22.
Fullerton M, Funder J: Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994;28:1863–1867.
23.
Cooper J: Effects of cytochalasin and phalloidin on actin. J Cell Biol 1987;105:1473–1478.
24.
Guarda E, Myers PR, Brilla CG, Tyagi SC, Weber KT: Endothelial cell induced modulation of cardiac fibroblast collagen metabolism. Cardiovasc Res 1993;27:1004–1008.
25.
Bayreuther K, Rodemann H, Hommel R, Dittmann K, Albiez M, Francz P: Human skin fibroblasts in vitro differentiate along a terminal cell lineage. Proc Natl Acad Sci USA 1988;85:5112–516.
26.
Rodemann HP, Muller GA, Knecht A, Norman JT, Fine LG: Fibroblasts of rabbit kidney in culture I. Characterization and identification of cell-specific markers. Am J Physiol 1991;261:F283–F291.
27.
Grupp C, Muller G: Renal fibroblast culture. Exp Nephrol 1999;7:377–385.
28.
Breen E, Falco V, Absher M, Cutroneo K: Subpopulations of rat lung fibroblasts with different amounts of type I and type III collagen mRNAs. J Biol Chem 1990;265:6286–6290.
29.
Harris K, Purkeson M, Yates J, Klahr S: Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 1990;15:16–23.
30.
Jandeleit-Dahm K, Cao Z, Cox A, Kelly D, Gilbert R, Cooper M: Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int 1999;56(suppl 71):S31–S36.
31.
Kim S, Han D, Lee H: Lovastatin inhibits transforming growth factor-β1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000;11:80–87.
32.
O’Donnell M, Kasiske B, Kim Y, Schmitz P, Keane W: Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 1993;22:83–89.
33.
O’Donnell M, Kasiske B, Kim Y, Atluru D, Keane W: Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993;91:83–87.
34.
Satoh T, Isobe H, Ayukawa K, Sakai H, Nawata H: The effects of pravastatin, an HMG-CoA reductase inhibitor, on cell viability and DNA production of rat hepatocytes. Life Sci 1996;59:1103–1108.
35.
Essig M, Nguyen G, Prie D, Escoubet B, Sraer J, Friedlander G: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ Res 1998;83:683–690.
36.
Kelynack K, Hewitson T, Nicholls K, Becker G, Jones C: Cell kinetics and tissue contraction following renal parenchymal cell death. Nephrology 1998;4:41–47.
37.
Norman J, Fine L: Progressive renal disease: fibroblasts, extracellular matrix, and integrins. Exp Nephrol 1999;7:167–177.
38.
Matrisian L: Metalloproteinases and their inhibitors in matrix remodelling. Trend Genet 1990;6:121–125.
39.
Turck J, Pollock A, Lovett D: Gelatinase A is a glomerular mesangial cell growth and differentiation factor. Kidney Int 1997;51:1397–1400.
40.
Serini G, Bochaton-Piallat M-L, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G: The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1. J Cell Biol 1998;142:873–881.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.